Elevar Therapeutics wins FDA approval for Lyrfigtu in bile duct cancer
Elevar Therapeutics has secured US Food and Drug Administration approval for Lyrfigtu (lirafugratinib), an oral, selective FGFR2 inhibitor indicated for patients with cholangiocarcinoma harbouring FGFR2 fusions or other rearrangements who have received prior treatment. The Fort Lee, New Jersey-based company said the drug is expected to reach patients in the US by the fourth quarter of 2026.
The approval is based on data from the Phase 1/2 ReFocus trial (NCT04526106), in which Lyrfigtu produced a confirmed objective response rate of 46% and a median duration of response of 11.8 months. Median progression-free survival was 11.3 months, with 49.2% of patients remaining progression-free at 12 months. Serious adverse events occurred in 32% of the 385 patients who received the drug; ocular toxicity, including retinal pigment epithelial detachment in 31% of patients, and hyperphosphataemia were the principal safety signals requiring monitoring and dose management.
What differentiates Lyrfigtu
Lyrfigtu's mechanism sets it apart from earlier agents in the FGFR inhibitor class. It binds FGFR2 covalently and irreversibly, which its developer says enables sustained target inhibition even against resistance mutations that can emerge with reversible first-generation inhibitors such as pemigatinib and infigratinib. Its selectivity for FGFR2 over related isoforms is also positioned as an advantage for reducing off-target toxicity, a known limitation of pan-FGFR agents.
Lipika Goyal, director of gastrointestinal oncology at the Stanford Cancer Center and lead author on the ReFocus study, said the drug "selectively targets FGFR2 while minimising off-isoform toxicities," adding that the mechanism addresses resistance that has limited earlier FGFR inhibitors. Alison Schram of Memorial Sloan Kettering Cancer Center separately noted that the results "reinforce the importance of molecular testing at diagnosis so that patients can be matched to therapies most likely to benefit them."
Market context and competitive landscape
Cholangiocarcinoma is rare, with approximately 8,000 new diagnoses annually in the US according to the American Cancer Society. Within that population, FGFR2 fusions or rearrangements occur predominantly in intrahepatic CCA and are found in roughly 10 to 16 percent of cases, creating a molecularly defined but commercially limited addressable population. Two FGFR inhibitors, Incyte's pemigatinib and QED Therapeutics' infigratinib, already hold approvals in the same second-line FGFR2-positive CCA setting, making competitive differentiation heavily dependent on the durability and depth of response data as well as tolerability profiles.
Elevar holds an exclusive worldwide commercialisation licence for lirafugratinib from Relay Therapeutics, which discovered the compound. The FDA granted the drug priority review in March 2026, a designation reserved for therapies that may offer significant improvements over available treatments in serious conditions. The parent company, South Korea-based HLB Co., adds manufacturing and commercial infrastructure to the partnership.
Beyond CCA, Elevar is evaluating Lyrfigtu in additional FGFR2-altered solid tumours, though any future indications will require separate regulatory submissions and approvals. Investors and clinicians will be watching enrolment progress in that expansion study, alongside real-world uptake data and payer coverage decisions in the existing indication, as the clearest near-term indicators of Lyrfigtu's commercial trajectory.